GlassScriptPhysician profile
Henry J Shapiro
NPI 1477591709
$11,985.20
in general payments reported to CMS, 2019-2025
70 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $590 · 2021: $1,729 · 2022: $1,929 · 2023: $2,330 · 2024: $2,163 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,615 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,615.37 |
| Education | $179.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,230.13 | 2019-2025 | |
| Celgene Corporation | $730.96 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $689.07 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $671.30 | 2019-2025 | Enhertu, Tagrisso |
| Incyte Corporation | $594.99 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $592.78 | 2019-2025 | Xtandi, Xospata, Padcev |
| Genzyme Corporation | $552.86 | 2020-2025 | |
| Genentech USA, INC. | $516.10 | 2019-2024 | Tecentriq, Venclexta, Alecensa |
| Merck Sharp & Dohme LLC | $448.15 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $416.36 | 2019-2025 | |
| Daiichi Sankyo INC. | $369.00 | 2020-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $315.14 | 2019-2025 | Opdualag, Opdivo, Reblozyl |
| Abbvie INC. | $292.27 | 2020-2025 | Venclexta |
| Amgen INC. | $273.97 | 2019-2023 | Kyprolis, Lumakras |
| Seagen INC. | $271.34 | 2019-2023 | Tukysa, Padcev, Tivdak |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $269.24 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Lilly USA, LLC | $237.48 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $225.94 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $219.41 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $193.27 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $168.56 | 2020-2025 | Onivyde, Somatuline Depot, Tazverik |
| Eisai INC. | $163.49 | 2021-2024 | |
| Sobi, INC | $161.42 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $153.10 | 2020-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $137.28 | 2022-2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $131.64 | 2019-2024 | Rezlidhia, Tavalisse |
| Adaptive Biotechnologies Corporation | $119.73 | 2022-2024 | Clonoseq |
| Sirtex Medical INC | $111.29 | 2022 | |
| Puma Biotechnology, INC. | $97.68 | 2020-2023 | |
| Caris Mpi, INC. | $96.14 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $92.98 | 2021 | |
| Stemline Therapeutics INC. | $91.63 | 2023-2025 | Orserdu |
| Amneal Pharmaceuticals LLC | $87.81 | 2024-2025 | Avastin, Neupogen, Neulasta |
| Aveo Pharmaceuticals, INC. | $75.93 | 2022-2025 | Fotivda |
| Kite Pharma, INC. | $71.59 | 2021-2023 | |
| Geron Corporation | $66.52 | 2025 | Rytelo |
| Exelixis INC. | $62.17 | 2021-2024 | Cabometyx |
| Pharmaessentia USA Corporation | $59.77 | 2024 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.73 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $55.63 | 2022-2024 | Libtayo |
| Servier Pharmaceuticals LLC | $48.51 | 2023 | |
| Emd Serono, INC. | $47.38 | 2023-2024 | Bavencio |
| Karyopharm Therapeutics INC. | $40.87 | 2020-2021 | |
| Legend Biotech USA INC. | $40.20 | 2024-2025 | Carvykti |
| Tg Therapeutics, INC. | $38.58 | 2021-2022 | |
| Cti Biopharma Corp. | $38.56 | 2022-2023 | Vonjo |
| Dendreon Pharmaceuticals LLC | $34.94 | 2025 | Provenge |
| Gilead Sciences, INC. | $34.29 | 2024-2025 | Trodelvy |
| Deciphera Pharmaceuticals INC. | $34.14 | 2021-2022 | |
| Mirati Therapeutics, INC. | $33.11 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $31.06 | 2021 | |
| Beone Medicines USA, INC. | $29.87 | 2025 | Tevimbra |
| Morphosys, US INC. | $29.50 | 2021 | |
| Pharmaand Gmbh | $27.93 | 2025 | Rubraca |
| Tolmar, INC. | $26.59 | 2025 | Rubraca, Eligard |
| Pharmacosmos Therapeutics INC. | $25.76 | 2025 | Monoferric |
| Biocon Biologics INC | $24.28 | 2024 | Fulphila |
| Fennec Pharmaceuticals, INC. | $21.84 | 2024 | Pedmark |
| Kyowa Kirin, INC. | $21.41 | 2021 | |
| Verity Pharmaceuticals INC. | $20.28 | 2025 | Trelstar |
| Immunogen, INC. | $19.84 | 2024 | Elahere |
| Taiho Oncology, INC. | $19.37 | 2024 | |
| Acceleron Pharma, INC. | $19.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.58 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.54 | 2024 | |
| Myovant Sciences INC. | $15.57 | 2021 | |
| Blueprint Medicines Corporation | $14.59 | 2021 | |
| Aurobindo Pharma USA, INC. | $13.87 | 2019 | |
| Sumitomo Pharma America, INC. | $13.63 | 2024 | Orgovyx |
| Advanced Accelerator Applications | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.